Houston Methodist suspends employees for refusing vaccine To view this email as a web page,
click here With $1.2B deal for molnupiravir, U.S. bets on Merck's oral COVID-19 antiviral Prime Day deal? Amazon lands FDA go-ahead to sell COVID-19 tests directly to consumers Houston Methodist makes good on threat to suspend employees who refused to get vaccinated Biden admin to purchase 500 million Pfizer COVID-19 vaccine doses to distribute to needy countries COVID-19 tracker: WTO set to begin vaccine supply negotiations CMS boosts Medicare payments for providers for administering at-home COVID-19 vaccinations Midstage cancer tests 'heavily impacted' by COVID-19 disruptions: survey PwC: Health costs to likely go up 6.5% in 2022 as systems invest in supply chain, digital health Regeneron's CEO, CSO pay under fire from advisory firms, who call on shareholders to oust a board member Featured Story | By Kevin Dunleavy Merck revealed a deal with the United States to supply 1.7 million courses of experimental COVID-19 oral treatment molnupiravir for $1.2 billion. This is Merck's last chance to develop a COVID-19 therapy after two vaccine attempts and another drug failed. read more |
| |
|---|
|
| | Benefits of Decentralized Clinical Trials To execute decentralized research strategies, sponsors are turning to an integrated supply chain solution known as Direct-to-Patient Services. This service allows patients to participate in clinical trials from their homes by providing them with study drugs and care where they live. Learn more. |
Top Stories By Andrea Park Just in time for its annual online sale event, Amazon has gotten the green light from the FDA to begin hawking its own COVID-19 test directly to consumers—potentially setting up the most coveted Prime Day deal of all. read more By Dave Muoio The health system had set a June 7 cutoff for all of its employees to receive COVID-19 vaccinations. The policy spurred protests and a lawsuit from those who opposed the mandatory policy. read more By Kevin Dunleavy The United States will purchase 500 million COVID-19 vaccine doses from Pfizer for distribution to needy countries around the world. Pfizer will deliver 200 million by the end of this year and the rest by the middle of next year, according to reports. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Members of the World Trade Organization have agreed to begin formal negotiations on a plan that would supply poorer nations with COVID-19 vaccine supplies, although they still remain split over IP waivers. The U.S. is reportedly set to buy 500 million Pfizer-BioNTech vaccines to donate to the rest of the world. And more headlines. read more By Robert King CMS announced an increase in Medicare payments for providers for administering COVID-19 vaccinations at a patient's home as the Biden White House seeks to expand the reach of vaccinations. read more By Ben Adams A new survey of biopharma execs has shown phase 2 oncology trials are the most disrupted. read more By Robert King Investments in digital health and preparing for the next pandemic are expected to help increase medical costs by up to 6.5% in 2022, a new report found. read more By Noah Higgins-Dunn Two influential shareholder advisory groups recommended Regeneron investors vote out board member George Sing, who sits on the compensation committee, in a rebuke against the company's "excessive" upfront stock awards for CEO Leonard Schleifer and CSO George Yancopoulos. read more | | Webinar: Accelerating NASH Clinical Trials Tuesday, June 15 | 10am ET / 7am PT Join industry leaders for a webinar dedicated to overcoming key challenges presented in NASH drug development. We’ll explore key considerations for liver biopsy collection and interpretation, emerging non-invasive biomarkers, and the connection between clinical practice and drug development. Register now. |
|
|
